Clinical Trials Logo

Adenocarcinomas clinical trials

View clinical trials related to Adenocarcinomas.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04699071 Recruiting - Adenocarcinomas Clinical Trials

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II non-randomized, multi-center study. The primary end point of this study is the objective response rate (ORR) at 24 weeks, using response evaluation criteria for solid tumors (RECIST) 1.1 criteria, for the combination therapy of continuous daily oral lenvatinib with three-weekly intravenous pembrolizumab in patients with recurrent clear cell carcinoma of gynecological origin (CCGC). The statistical design is Simon's minimax two-stage design and the present study aims to complete stage 1 of the Simon's two-stage design.